Clinical Trials
14 trialsNCT05327530 2026-04-24
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
EMD Serono
Phase 2 Active not recruiting
NCT07460245 2026-03-10
AVESEC
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Not yet recruiting
NCT04848519 2026-02-19
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
Emory University
Phase 2 Active not recruiting
NCT04701918 2026-01-22
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT03744793 2026-01-09
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04678362 2025-09-22
TALASUR
Centre Francois Baclesse
Phase 2 Recruiting
NCT04887831 2025-09-08
PRESERVE3
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT04322643 2025-02-25
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT06424717 2024-09-27
Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)
EMD Serono
Phase 2 Withdrawn
NCT05574504 2024-08-01
Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
AdventHealth
Phase 2 Withdrawn
NCT03390595 2023-10-18
INDUCOMAIN
Associació per a la Recerca Oncologica, Spain
Phase 2 Completed
NCT05600127 2023-09-08
CHASIT
Erasmus Medical Center
Phase 2 Recruiting
NCT05107427 2023-04-18
AVENU
4D pharma plc
Phase 2 Withdrawn